Recent Advances and Clinical Trials
China has been making significant strides in the research and development of psoriasis ointments, with several new drugs entering clinical trials and showing promising results. One notable development is the approval of KYHY2302 cream, a Class 1 chemical drug for psoriasis treatment, for clinical trials by the National Medical Products Administration (NMPA). This cream, developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and Jiangsu Kangyuan Pharmaceutical Co., Ltd., has demonstrated excellent inhibitory activity against phosphodiesterase 4 (PDE4) and anti-inflammatory effects at the cellular level. It is expected to provide a safe and effective treatment option for psoriasis patients.
Another significant advancement is the development of SIM0335 (Secukinumab ointment) by Simcere Pharmaceuticals. This ointment, which completed its first patient enrollment in a Phase II clinical trial in May 2022, is designed to treat mild to moderate plaque psoriasis. The active ingredient, CKBA, regulates the differentiation of Th17 cells and inhibits the secretion of IL-17A, a key cytokine involved in psoriasis.
Current Treatments and Guidelines
The 2023 edition of the “Guidelines for the Diagnosis and Treatment of Psoriasis in China” provides comprehensive recommendations for the use of topical treatments. It emphasizes the importance of moisturizers, corticosteroids, vitamin D3 analogs, and other topical agents in managing psoriasis. The guidelines also highlight the need for individualized treatment plans based on the severity of the disease and patient-specific factors.
Market and Industry Analysis
The market for psoriasis treatments in China is growing, driven by the increasing prevalence of the disease and the need for more effective therapies. The industry is characterized by a mix of traditional chemical drugs and newer biologics, with the latter gaining prominence in recent years. The inclusion of psoriasis drugs in China’s national medical insurance catalog has also improved patient access to treatments.
Future Outlook
Ongoing research and clinical trials are expected to bring more innovative treatments to market. The focus on developing non-steroidal, safe, and effective topical agents is likely to improve patient outcomes and quality of life. Continued investment in R&D, combined with supportive policies from the government, will further drive advancements in this field.
Related topics:
